Active Ingredient History
Spartalizumab is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma of Lung (Phase 2)
Adenoma, Oxyphilic (Phase 2)
Bone Marrow Diseases (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 1/Phase 2)
Esophageal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 2)
Hematologic Diseases (Phase 1)
Histology (Phase 2)
Immunotherapy (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 1)
Leukemia, Myeloid (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Liver Neoplasms (Phase 1)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Melanoma (Phase 3)
Mesothelioma (Phase 2)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasms (Phase 2)
Neuroendocrine Tumors (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Polycythemia Vera (Phase 1)
Preleukemia (Phase 1)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 2)
Rectal Neoplasms (Phase 2)
Sarcoma (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Thoracic Injuries (Phase 2)
Thyroid Cancer, Papillary (Phase 2)
Thyroid Carcinoma, Anaplastic (Phase 1/Phase 2)
Thyroid Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue